BUZZ-Arrowhead stock surges due to early-stage Alzheimer's drug trial data

October 14 - ** Shares of pharmaceutical company Arrowhead Pharmaceuticals (ARWR.O) rose 6.7% in premarket trading to $62

** The company stated that its experimental Alzheimer’s drug ARO-MAPT (link) lowered the average level of tau protein related to the disease in the cerebrospinal fluid of healthy volunteers by 73% in early to mid-stage clinical trials, with a maximum reduction of 85%

** The abnormal accumulation of tau protein is considered a key trigger for Alzheimer’s disease and other neurodegenerative brain disorders

** The company stated that the reduction in protein levels lasted at least three months after the final dose, supporting the feasibility of once-per-quarter dosing

** The company is currently testing the drug in early-stage Alzheimer’s patients and expects to release new data in 2027

** As of the previous trading day’s close, the stock had fallen about 12% so far this year

(To facilitate non-native English speakers, Reuters has automated its reports into several other languages. Since automated translation may contain errors or may not include the intended context, Reuters does not guarantee the accuracy of this translation and provides it solely for the convenience of readers. Reuters accepts no liability for any damages or losses caused by the use of the automated translation function.)